Hostname: page-component-76fb5796d-2lccl Total loading time: 0 Render date: 2024-04-26T20:52:27.863Z Has data issue: false hasContentIssue false
  • English
  • Français

IL-1β in breast cancer bone metastasis

Published online by Cambridge University Press:  01 March 2022

Jiabao Zhou ,
Claudia Tulotta  and
Penelope D. Ottewell Open the ORCID record for Penelope D. Ottewell [Opens in a new window]
Jiabao Zhou
Affiliation:
Department of Oncology and Metabolism, University of Sheffield, Beech Hill Road, SheffieldS10 2RX, UK
Claudia Tulotta
Affiliation:
Institute for Experimental Pathology (ExPat), Center for Molecular Biology of Inflammation (ZMBE), Westfälische Wilhelms-Universität (WWU), 48149Münster, Germany
Penelope D. Ottewell*
Affiliation:
Department of Oncology and Metabolism, University of Sheffield, Beech Hill Road, SheffieldS10 2RX, UK
*
Author for correspondence: Penelope D. Ottewell, E-mail: p.d.ottewell@sheffield.ac.uk
Get access Rights & Permissions [Opens in a new window]

Abstract

Bone is the most common site for advanced breast cancer to metastasise. The proinflammatory cytokine, interleukin-1β (IL-1β) plays a complex and contradictory role in this process. Recent studies have demonstrated that breast cancer patients whose primary tumours express IL-1β are more likely to experience relapse in bone or other organs. Importantly, IL-1β affects different stages of the metastatic process including growth of the primary tumour, epithelial to mesenchymal transition (EMT), dissemination of tumour cells into the blood stream, tumour cell homing to the bone microenvironment and, once in bone, this cytokine participates in the interaction between cancer cells and bone cells, promoting metastatic outgrowth at this site. Interestingly, although inhibition of IL-1β signalling has been shown to have potent anti-metastatic effects, inhibition of the activity of this cytokine has contradictory effects on primary tumours, sometimes reducing but often promoting their growth. In this review, we focus on the complex roles of IL-1β on breast cancer bone metastasis: specifically, we discuss the distinct effects of IL-1β derived from tumour cells and/or microenvironment on inhibition/induction of primary breast tumour growth, induction of the metastatic process through the EMT, promotion of tumour cell dissemination into the bone metastatic niche and formation of overt metastases.

Keywords

Anti- and pro-tumour immune responsebone metastasisbreast cancerIL-1β
Type
Review
Information
Expert Reviews in Molecular Medicine , Volume 24 , 2022 , e11
Copyright
Copyright © The Author(s), 2022. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Sung, H et al. (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 71, 209–249.Google Scholar
Yang, M et al. (2019) Skeletal-related adverse events during bone metastasis of breast cancer: current status. Discovery Medicine 27, 211–220.Google ScholarPubMed
Coleman, R et al. (2012) Effects of bone-targeted agents on cancer progression and mortality. Journal of the National Cancer Institute 104, 1059–1067.CrossRefGoogle ScholarPubMed
Pérez-Ramírez, C et al. (2017) Interleukins as new prognostic genetic biomarkers in non-small cell lung cancer. Surgical Oncology 26, 278–285.CrossRefGoogle ScholarPubMed
Tulotta, C et al. (2019) Endogenous production of IL1B by breast cancer cells drives metastasis and colonization of the bone microenvironment. Clinical Cancer Research 25, 2769–2782.CrossRefGoogle ScholarPubMed
Zabaleta, J et al. (2009) Cytokine genetic polymorphisms and prostate cancer aggressiveness. Carcinogenesis 30, 1358–1362.CrossRefGoogle ScholarPubMed
Tengesdal, IW et al. (2021) Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion. Proceedings of the National Academy of Sciences 118, e2000915118.CrossRefGoogle ScholarPubMed
Gelfo, V et al. (2020) Roles of IL-1 in cancer: from tumor progression to resistance to targeted therapies. International Journal of Molecular Sciences 21, 6009.CrossRefGoogle ScholarPubMed
Di Paolo, NC and Shayakhmetov, DM (2016) Interleukin 1α and the inflammatory process. Nature Immunology 17, 906–913.CrossRefGoogle ScholarPubMed
Rébé, C and Ghiringhelli, F (2020) Interleukin-1β and cancer. Cancers 12, 1791.CrossRefGoogle ScholarPubMed
Kiss, M et al. (2021) Inflammasome- and gasdermin D-independent IL-1β production mobilizes neutrophils to inhibit antitumor immunity. Cancer Immunology Research 9, 309–323.CrossRefGoogle Scholar
Wu, T-C et al. (2018) IL1 receptor antagonist controls transcriptional signature of inflammation in patients with metastatic breast cancer. Cancer Research 78, 5243–5258.CrossRefGoogle Scholar
Tulotta, C et al. (2021) IL-1B drives opposing responses in primary tumours and bone metastases; harnessing combination therapies to improve outcome in breast cancer. NPJ Breast Cancer 7, 1–15.CrossRefGoogle ScholarPubMed
Lappano, R et al. (2020) The IL1β-IL1R signaling is involved in the stimulatory effects triggered by hypoxia in breast cancer cells and cancer-associated fibroblasts (CAFs). Journal of Experimental & Clinical Cancer Research 39, 1–22.CrossRefGoogle Scholar
Nutter, F et al. (2014) Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone: evidence using a novel bone-seeking cell line. Endocrine-Related Cancer 21, 327–341.CrossRefGoogle ScholarPubMed
Vilsmaier, T et al. (2016) Influence of circulating tumour cells on production of IL-1α, IL-1β and IL-12 in sera of patients with primary diagnosis of breast cancer before treatment. Anticancer Research 36, 5227–5236.CrossRefGoogle ScholarPubMed
Lefley, D et al. (2019) Development of clinically relevant in vivo metastasis models using human bone discs and breast cancer patient-derived xenografts. Breast Cancer Research 21, 1–21.CrossRefGoogle ScholarPubMed
Eyre, R et al. (2019) Microenvironmental IL1β promotes breast cancer metastatic colonisation in the bone via activation of Wnt signalling. Nature Communications 10, 1–15.CrossRefGoogle ScholarPubMed
Holen, I et al. (2016) IL-1 drives breast cancer growth and bone metastasis in vivo. Oncotarget 7, 75571.CrossRefGoogle ScholarPubMed
Voloshin, T et al. Blocking IL1b Pathway Following Paclitaxel Chemotherapy Slightly Inhibits Primary Tumor Growth but Promotes Spontaneous Metastasis.Google Scholar
Guo, B et al. (2016) Targeting inflammasome/IL-1 pathways for cancer immunotherapy. Scientific Reports 6, 1–12.Google ScholarPubMed
Van Den Eeckhout, B et al. (2020) Interleukin-1 as innate mediator of T cell immunity. Frontiers in Immunology 11, 621921.Google ScholarPubMed
Li, Y et al. (2012) IL-1β promotes stemness and invasiveness of colon cancer cells through Zeb1 activation. Molecular Cancer 11, 1–13.CrossRefGoogle ScholarPubMed
Castaño, Z et al. (2018) IL-1β inflammatory response driven by primary breast cancer prevents metastasis-initiating cell colonization. Nature Cell Biology 20, 1084–1097.CrossRefGoogle ScholarPubMed
Riggio, AI et al. (2021) The lingering mysteries of metastatic recurrence in breast cancer. British Journal of Cancer 124, 13–26.CrossRefGoogle ScholarPubMed
Hüsemann, Y et al. (2008) Systemic spread is an early step in breast cancer. Cancer Cell 13, 58–68.CrossRefGoogle ScholarPubMed
Sosa, MS et al. (2014) Mechanisms of disseminated cancer cell dormancy: an awakening field. Nature Reviews Cancer 14, 611–622.CrossRefGoogle ScholarPubMed
Lamouille, S et al. (2014) Molecular mechanisms of epithelial–mesenchymal transition. Nature Reviews Molecular Cell Biology 15, 178–196.CrossRefGoogle ScholarPubMed
Najafi, M et al. (2019) Extracellular matrix (ECM) stiffness and degradation as cancer drivers. Journal of Cellular Biochemistry 120, 2782–2790.CrossRefGoogle ScholarPubMed
Oh, K et al. (2016) IL-1β induces IL-6 production and increases invasiveness and estrogen-independent growth in a TG2-dependent manner in human breast cancer cells. BMC Cancer 16, 1–11.CrossRefGoogle Scholar
Mon, NN et al. (2017) Interleukin-1β activates focal adhesion kinase and Src to induce matrix metalloproteinase-9 production and invasion of MCF-7 breast cancer cells. Oncology Letters 13, 955–960.CrossRefGoogle ScholarPubMed
Perez-Yepez, EA et al. (2014) A novel β-catenin signaling pathway activated by IL-1β leads to the onset of epithelial–mesenchymal transition in breast cancer cells. Cancer Letters 354, 164–171.CrossRefGoogle Scholar
Fahey, E and Doyle, SL (2019) IL-1 family cytokine regulation of vascular permeability and angiogenesis. Frontiers in Immunology 10, 1426.CrossRefGoogle ScholarPubMed
Voronov, E et al. (2014) The role IL-1 in tumor-mediated angiogenesis. Frontiers in Physiology 5, 114.CrossRefGoogle ScholarPubMed
Brown, H et al. (2012) Location matters: osteoblast and osteoclast distribution is modified by the presence and proximity to breast cancer cells in vivo. Clinical & Experimental Metastasis 29, 927–938.CrossRefGoogle ScholarPubMed
Ottewell, PD (2016) The role of osteoblasts in bone metastasis. Journal of Bone Oncology 5, 124–127.CrossRefGoogle ScholarPubMed
Allocca, G et al. (2019) The bone metastasis niche in breast cancer: potential overlap with the haematopoietic stem cell niche in vivo. Journal of Bone Oncology 17, 100244.CrossRefGoogle ScholarPubMed
Wang, J et al. (2006) The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis. Cancer and Metastasis Reviews 25, 573–587.CrossRefGoogle ScholarPubMed
Valdivia-Silva, JE et al. (2009) Effect of pro-inflammatory cytokine stimulation on human breast cancer: implications of chemokine receptor expression in cancer metastasis. Cancer Letters 283, 176–185.CrossRefGoogle ScholarPubMed
Escobar, P et al. (2015) IL-1β produced by aggressive breast cancer cells is one of the factors that dictate their interactions with mesenchymal stem cells through chemokine production. Oncotarget 6, 29034.CrossRefGoogle ScholarPubMed
Klein, CA (2009) Parallel progression of primary tumours and metastases. Nature Reviews Cancer 9, 302–312.CrossRefGoogle ScholarPubMed
George, CN et al. (2020) Oestrogen and zoledronic acid driven changes to the bone and immune environments: potential mechanisms underlying the differential anti-tumour effects of zoledronic acid in pre-and post-menopausal conditions. Journal of Bone Oncology 25, 100317.CrossRefGoogle Scholar
Braun, S et al. (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. New England Journal of Medicine 353, 793–802.CrossRefGoogle ScholarPubMed
Tjensvoll, K et al. (2019) Detection of disseminated tumor cells in bone marrow predict late recurrences in operable breast cancer patients. BMC Cancer 19, 1–11.CrossRefGoogle ScholarPubMed
Jahanban-Esfahlan, R et al. (2019) Tumor cell dormancy: threat or opportunity in the fight against cancer. Cancers 11, 1207.CrossRefGoogle ScholarPubMed
Tulotta, C and Ottewell, P (2018) The role of IL-1B in breast cancer bone metastasis. Endocrine-Related Cancer 25, R421–R434.CrossRefGoogle ScholarPubMed
Lawson, DA et al. (2015) Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature 526, 131–135.CrossRefGoogle ScholarPubMed
Balic, M et al. (2006) Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clinical Cancer Research 12, 5615–5621.CrossRefGoogle ScholarPubMed
Sarmiento-Castro, A et al. (2020) Increased expression of interleukin-1 receptor characterizes anti-estrogen-resistant ALDH+ breast cancer stem cells. Stem Cell Reports 15, 307–316.CrossRefGoogle ScholarPubMed
Rao, S et al. (2018) RANKL and RANK: from mammalian physiology to cancer treatment. Trends in Cell Biology 28, 213–223.CrossRefGoogle ScholarPubMed
He, Z et al. (2020) Evaluation of genetic variants in IL-1B and its interaction with the predisposition of osteoporosis in the northwestern Chinese Han population. The Journal of Gene Medicine 22, e3214.CrossRefGoogle ScholarPubMed
Voigt, C et al. (2017) Cancer cells induce interleukin-22 production from memory CD4+ T cells via interleukin-1 to promote tumor growth. Proceedings of the National Academy of Sciences 114, 12994–12999.CrossRefGoogle ScholarPubMed
Kaplanov, I et al. (2019) Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti–PD-1 for tumor abrogation. Proceedings of the National Academy of Sciences 116, 1361–1369.CrossRefGoogle ScholarPubMed
Silvestre-Roig, C et al. (2016) Neutrophil heterogeneity: implications for homeostasis and pathogenesis. Blood. The Journal of the American Society of Hematology 127, 2173–2181.Google ScholarPubMed
Ohms, M et al. (2020) An attempt to polarize human neutrophils toward N1 and N2 phenotypes in vitro. Frontiers in Immunology 11, 532.CrossRefGoogle ScholarPubMed
Chen, LC et al. (2012) Tumour inflammasome-derived IL-1β recruits neutrophils and improves local recurrence-free survival in EBV-induced nasopharyngeal carcinoma. EMBO Molecular Medicine 4, 1276–1293.CrossRefGoogle ScholarPubMed
Szczerba, BM et al. (2019) Neutrophils escort circulating tumour cells to enable cell cycle progression. Nature 566, 553–557.CrossRefGoogle ScholarPubMed
Zeindler, J et al. (2019) Infiltration by myeloperoxidase-positive neutrophils is an independent prognostic factor in breast cancer. Breast Cancer Research and Treatment 177, 581–589.CrossRefGoogle ScholarPubMed
Xiao, Y et al. (2021) Cathepsin C promotes breast cancer lung metastasis by modulating neutrophil infiltration and neutrophil extracellular trap formation. Cancer Cell 39, 423–437. e427.CrossRefGoogle ScholarPubMed
Zhao, L et al. (2018) Pharmacological activation of estrogen receptor beta augments innate immunity to suppress cancer metastasis. Proceedings of the National Academy of Sciences 115, E3673–E3681.CrossRefGoogle ScholarPubMed
Gomes, T et al. (2019) IL-1β blockade attenuates thrombosis in a neutrophil extracellular trap-dependent breast cancer model. Frontiers in Immunology 10, 2088.CrossRefGoogle Scholar
Chen, Y et al. (2019) Tumor-associated macrophages: an accomplice in solid tumor progression. Journal of Biomedical Science 26, 1–13.CrossRefGoogle ScholarPubMed
Hou, Z et al. (2011) Macrophages induce COX-2 expression in breast cancer cells: role of IL-1β autoamplification. Carcinogenesis 32, 695–702.CrossRefGoogle ScholarPubMed
Jang, J-H et al. (2020) Breast cancer cell–derived soluble CD44 promotes tumor progression by triggering macrophage IL1β production. Cancer Research 80, 1342–1356.Google ScholarPubMed
Hao, N-B et al. (2012) Macrophages in tumor microenvironments and the progression of tumors. Clinical and Developmental Immunology 2012, 948098.CrossRefGoogle ScholarPubMed
Welte, T et al. (2016) Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation. Nature Cell Biology 18, 632–644.CrossRefGoogle ScholarPubMed
Bunt, SK et al. (2006) Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. The Journal of Immunology 176, 284–290.CrossRefGoogle ScholarPubMed
Coffelt, SB et al. (2015) IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis. Nature 522, 345–348.CrossRefGoogle Scholar
Ridker, PM et al. (2017) Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. The Lancet 390, 1833–1842.CrossRefGoogle ScholarPubMed